From the beginning, AiCuris’ success has been the result of strong internal expertise leveraged by dynamic and fruitful collaborations.
AiCuris is constantly evaluating strategic partnerships and collaboration opportunities with biotech or pharmaceutical companies. Our focus is the out-licensing of projects after clinical proof-of-concept (PoC), though we remain open for exploratory discussions at an earlier stage e.g. interest in co-development of a given project or in joining efforts to develop compounds.
As proof of AiCuris’ success as world-class partner in the anti-infective field, in 2012 AiCuris entered into an exclusive worldwide license agreement for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including Letermovir, with Merck & Co., USA (MSD).
If you have further questions regarding partnering of our projects please contact: